MagAssist Medical Named to MedTech Outlook's APAC Top 10 Medtech Companies 2022 Amid IPO Filing

Committed toPromote Technological Innovation in Life Support Equipment

SuzhouJanuary 31, 2023/PR Newswire/ -- In January 2023, the internationally authoritative medical technology magazine MedTech Outlook published2022Asia-Pacific Medical Technology Enterprises in 202310Strong List (Top 10 Medtech Companies in APAC - 2022)。magAssist, as a company with outstanding contributions in the field of life support, due to itsIn"Clinical Needs-Oriented, Multi-Product Lines Providing Comprehensive Support for Medical Professionals"The concept and innovative model successfully made the list., and was featured on the cover story of the Asia-Pacific Annual Special Issue.

magAssist's Self-Developed Core Product--Extracorporeal Magnetic Levitation Artificial Heart MoyoAssist^®️Extra-VAD, has completed patient enrollment for all clinical trials at 12 centers across China, with overall treatment outcomes proving satisfactory. In the new year, it is expected to become China's first extracorporeal magnetically levitated artificial heart to be officially put into clinical use, aiding more patients.

MedTech Outlook is an internationally renowned professional media outlet in the field of medical technology, dedicated to tracking the latest trends, challenges, and innovative solutions in the healthcare technology sector. Impacted by the global COVID-19 pandemic, disease patterns and demographic structures have undergone drastic changes, creating an urgent need for innovative technologies to provide better disease management support for patients.MedTech OutlookIn"The Future of Patients"As the annual theme, ten high-end medical technology companies that adhere to patient-centered care and are at the forefront of innovation were recognized.

"Technology that meets clinical needs can truly create value."

The artificial heart is one of the most advanced medical devices in the field of emergency and critical care, capable of helping heart failure patients through the dangerous period of emergency treatment and creating opportunities for further treatment or transplantation. Currently, there is a huge clinical demand in China for surgical assistance and treatment methods for heart failure. However, most of the high-end life support equipment used at this stage are imported products. It is urgent to accelerate domestic independent research and development to provide better product services for doctors and patients.

magAssist is one of the few medical device companies in China that focuses on the field of medium- and short-term life support., its self-developed extracorporeal magnetically levitated artificial heart, blood compatibility, support time, and flow rateBoth have reached world-leading levels.。

At the same time, in order to effectively address the key pain points of clinical needs in China, magAssist's extracorporeal magnetic levitation artificial heart was jointly developed with Wuhan Union Hospital. In 2022, Professor Dong Nianguo's team from Wuhan Union achieved the first minimally invasive implantation surgery of an extracorporeal magnetic levitation artificial heart in China, minimizing patient trauma. The product has now completed patient enrollment for all clinical trials in China, with more than half of the patients having received the MoyoAssist through minimally invasive procedures.^®️Extra-VAD, with ideal treatment outcomes.

(Photo) Professor Dong Nianguo's team from Wuhan Union Hospital with patients

"magAssist's multi-product pipeline will play a role in '1+1>2'Clinical Benefits"

Due to the complexity of heart failure conditions, there is no one-for-all product in clinical practice for different disease stages and patient populations.magAssist has chosen a multi-product pipeline development path, starting with and focusing on the extracorporeal magnetically levitated artificial heart, linking other organ modules to build an intelligent, interconnected multi-organ extracorporeal life support platform.magAssist has now developed product lines including extracorporeal magnetic levitation artificial heart, minimally invasive interventional artificial heart, a new generation of portable extracorporeal membrane oxygenation system (ECMO), and a warm blood organ transport platform.

In the field of interventional artificial hearts, how to achieve greater support flow and longer support duration with smaller interventional sizes is a current direction of exploration for many companies. magAssist has developedCurrentlyThe Smallest in the WorldArtificial HeartNyokAssist™, with an intervention size of only9Fr`, thinner than an earphone jack`, Based on the "foldable" flexible mechanical configuration technology, the hydraulic performance and blood compatibility have been optimized. While maintaining a larger flow rate, the level of invasiveness and vascular complications has been reduced. The product has completed animal experiments after the final round of improvements and has been submitted for registration inspection.

magAssist's Self-Developed Next-Generation Portable ECMO--BreathMoAssist™, effectively addresses clinical pain points such as multiple complications and low convenience.。Another product, the warm blood organ transport platform DonorLife™, achieved stable beating of an animal heart for over 13 hours after being removed from the body in the most recent animal experiment. Unlike the commonly used cold ischemia protection method, it significantly breaks through the current preservation time and transportation distance while reducing damage to the heart, bringing a revolution to donor transport in heart transplantation.

MedTech OutlookCommented:"magAssist, as a pioneer of China's medical device industry, has come a long way, and its outstanding achievements in this field also herald a new future full of opportunities for the healthcare industry."

In the future, magAssist will achieve effective coordination for multi-organ support in acute and critical care scenarios, assist medical professionals in improving treatment outcomes, reduce nursing costs and equipment usage barriers, and provide better treatment solutions for patients in China and even globally.